Search International and National Patent Collections
Some content of this application is unavailable at the moment.
If this situation persists, please contact us atFeedback&Contact
1. (KR1020180088401) 3-(5-아미노-2-메틸-4-옥소-4H-퀴나졸린-3-일)-피페리딘-2,6-다이온을 사용한 주기 요법

Office : Republic of Korea
Application Number: 1020187015154 Application Date: 01.12.2016
Publication Number: 1020180088401 Publication Date: 03.08.2018
Publication Kind : A
Prior PCT appl.: Application Number: ; Publication Number:WO2017096024 Click to see the data
IPC:
A61K 31/517
A61K 45/06
A61K 9/00
A61P 35/00
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
495
having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
505
Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
517
ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
45
Medicinal preparations containing active ingredients not provided for in groups A61K31/-A61K41/132
06
Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9
Medicinal preparations characterised by special physical form
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35
Antineoplastic agents
Applicants: 셀진 코포레이션
Inventors: 하그너, 패트릭
간디, 애니타
포르데나드, 마이클
Agents: 특허법인 광장리앤고
Priority Data: 62/262,263 02.12.2015 US
Title: (KO) 3-(5-아미노-2-메틸-4-옥소-4H-퀴나졸린-3-일)-피페리딘-2,6-다이온을 사용한 주기 요법
Abstract: front page image
(KO) 본 명세서에는 림프종을 비롯한 암을 치료, 예방 및/또는 관리하는 방법이 제공되며, 이 방법은 환자에게 3-(5-아미노-2-메틸-4-옥소-4-퀴나졸린-3-일)-피페리딘-2,6-다이온, 또는 이의 거울상이성질체 또는 거울상이성질체의 혼합물, 또는 이의 약제학적으로 허용 가능한 염, 용매화물, 수화물, 공-결정, 포접 화합물, 또는 다형체를 주기 요법 치료요법으로 투여하는 단계를 포함한다. H
Also published as:
AU2016364753CA3006758SG11201804367PIL259597EP3383398MX2018006779
BR112018010964EA201891289WO/2017/096024